Hydrops fetalis is a serious condition in which abnormal amounts of fluid build up in two or more areas of an unborn baby’s body. These fluid collections can appear around the lungs, heart, or abdomen, or as widespread swelling under the skin. It affects roughly 1 in 1,500 to 3,800 births, and because of its severity, it often requires specialized prenatal care and intervention.
How Fluid Builds Up in the Fetus
In a healthy pregnancy, fluid moves constantly between a baby’s bloodstream, tissues, and lymphatic system in a careful balance. Hydrops fetalis develops when something disrupts that balance, causing fluid to leak out of blood vessels faster than it can be reabsorbed. Four basic mechanisms can trigger this: increased pressure inside tiny blood vessels pushing fluid outward, low protein levels in the baby’s blood (which normally help pull fluid back in), blockages in the lymphatic system that prevent fluid from draining, and direct damage to blood vessel walls that makes them leaky.
The result is the same regardless of the trigger. Fluid pools in body cavities and under the skin, putting pressure on developing organs. When fluid collects around the lungs, it can compress them and interfere with growth. Fluid around the heart can restrict its ability to pump. The swelling can become severe enough to threaten the baby’s life before birth.
Immune vs. Non-Immune Types
Hydrops fetalis falls into two categories based on what’s driving the fluid buildup.
Immune hydrops happens when the mother’s immune system attacks the baby’s red blood cells. This occurs most often when the mother and baby have incompatible blood types, particularly involving the Rh factor. The mother’s antibodies cross the placenta, destroy fetal red blood cells, and cause severe anemia. The baby’s heart works harder to compensate, eventually leading to fluid overload. Thanks to routine Rh screening and preventive treatment during pregnancy, immune hydrops has become far less common than it once was.
Non-immune hydrops accounts for the large majority of cases today and has a long list of potential causes. It affects an estimated 1 in 1,700 to 3,000 pregnancies, though only about 1 in 4,000 live births, because many affected pregnancies end in loss or termination. Identifying the underlying cause is critical because treatment depends entirely on what’s going wrong.
Common Causes of Non-Immune Hydrops
Heart problems are the single most common category, responsible for roughly 20% of non-immune cases. Structural heart defects can raise pressure in the baby’s veins, forcing fluid out of blood vessels and into surrounding tissues. Abnormal heart rhythms, particularly very fast heartbeats, can prevent the heart from filling properly between beats, creating the same kind of pressure backup.
Genetic and chromosomal conditions make up another major group. Certain chromosome abnormalities, inherited metabolic disorders, and genetic syndromes like Noonan syndrome can all lead to hydrops through various pathways, from impaired heart function to abnormal lymphatic development.
Infections passed from mother to baby during pregnancy are another well-known trigger. Certain viral infections can suppress the baby’s bone marrow, leading to severe anemia and eventually fluid accumulation. Complications specific to identical twins sharing a placenta, tumors involving the placenta, and problems with the baby’s blood-forming system round out the most frequently identified causes. In some cases, no cause is found despite extensive testing.
How Hydrops Fetalis Is Diagnosed
The condition is almost always detected on ultrasound during a routine prenatal scan or during targeted imaging ordered for other concerns. The formal diagnosis requires visible fluid accumulation in at least two separate body compartments: fluid in the abdomen (ascites), fluid around the lungs (pleural effusion), fluid around the heart (pericardial effusion), or generalized skin swelling. An abnormally thickened placenta often accompanies these findings.
Once hydrops is identified, the next step is determining why it’s happening. Blood work on the mother checks for antibodies that would indicate immune hydrops and screens for infections. If immune causes are ruled out, genetic testing becomes essential. The standard starting point is a chromosomal microarray, which detects missing or extra segments of DNA. If that comes back normal, broader testing like exome sequencing, which evaluates most known disease-causing genes in a single test, provides a high additional chance of finding an answer. Some commercial gene panels can now screen over 130 genes associated with non-immune hydrops simultaneously. Biochemical testing for metabolic disorders and targeted panels for specific conditions like Noonan syndrome may also be recommended depending on the ultrasound findings.
Treatment Options During Pregnancy
Treatment varies dramatically depending on the underlying cause, which is why pinpointing a diagnosis matters so much.
For immune hydrops and other causes of severe fetal anemia, the primary treatment is an intrauterine blood transfusion. A specialist delivers blood directly to the baby through the umbilical cord, guided by ultrasound. This procedure can be repeated as needed throughout pregnancy and has a strong track record of improving outcomes when anemia is the core problem.
For non-immune cases, interventions target the specific underlying issue. A baby with an abnormally fast heart rhythm may respond to medication given to the mother, which crosses the placenta and slows the baby’s heart rate. Fluid collections that are compressing the lungs or other organs can sometimes be drained through a small shunt placed during pregnancy. Specialized fetal treatment centers are also developing newer approaches like in utero enzyme replacement therapy for certain metabolic conditions. In cases where the underlying cause cannot be treated before birth, the focus shifts to close monitoring and planning the timing and location of delivery to give the baby the best chance.
Risks to the Mother
Hydrops fetalis doesn’t only affect the baby. A condition called Mirror Syndrome (also known as Ballantyne syndrome) can develop in the mother, where she begins to mirror the baby’s fluid-overloaded state. The hallmark is a triad of findings: a swollen fetus, an abnormally thick placenta, and maternal edema.
Mirror Syndrome closely resembles preeclampsia and can be difficult to distinguish from it. In documented cases, virtually all affected mothers experienced significant weight gain, and 90% developed high blood pressure. Other symptoms include shortness of breath, headache, visual disturbances, and swelling in the legs, face, or hands. Lab work typically shows a drop in red blood cell counts, low protein levels in the blood, and elevated uric acid. Both Mirror Syndrome and preeclampsia involve widespread dysfunction of blood vessel walls, which explains the overlap in symptoms. Recognizing Mirror Syndrome is important because the maternal symptoms generally improve once the fetal hydrops is treated or the pregnancy is delivered.
Outlook and What Affects Survival
The prognosis for hydrops fetalis depends heavily on the cause. Immune hydrops caused by Rh incompatibility, once a leading cause of newborn death, now has much better outcomes thanks to intrauterine transfusions and modern neonatal care. Non-immune hydrops carries a more guarded prognosis overall, though individual cases vary widely.
Several factors influence how things turn out. Babies whose hydrops is caused by a treatable condition, like an abnormal heart rhythm that responds to medication, tend to do considerably better than those with severe structural abnormalities or chromosomal disorders. How early in pregnancy the hydrops appears also matters: earlier onset generally signals a more serious underlying problem. The number of fluid-filled compartments at diagnosis, the presence of additional birth defects, and whether a specific cause can be identified all play into the overall picture.
The gap between the number of pregnancies affected (1 in 1,700 to 3,000) and the number of live births with the condition (roughly 1 in 4,000) reflects the reality that many cases result in pregnancy loss or a decision to end the pregnancy after a serious underlying diagnosis is confirmed. For babies who are born alive, survival depends on access to specialized neonatal intensive care and, in many cases, the ability to treat the root cause in the days and weeks after birth.